Article By:
White Diamond Research
Wednesday, July 12, 2017 11:04 AM EDT
Delcath is engaging in death spiral financing, and the convertible note holders can buy shares at a 15% discount to the recent market price and immediately sell. It's clinical trials are on the same technology that the FDA failed to approve in 2013.
In this article: DCTH
